ANI Pharmaceuticals, Inc. filings document financial results, operating updates, governance matters, and material events for its Rare Disease, Generics, and Brands businesses. Form 8-K reports furnish earnings releases, preliminary results, guidance updates, Regulation FD investor presentations, and corporate changes such as independent auditor matters.
ANI proxy filings cover shareholder voting items, board governance, executive compensation, equity awards, and related governance disclosures. The filing record also provides formal context for product and business risks tied to biopharmaceutical development, FDA-regulated generic launches, branded products, commercialization, manufacturing, and capital actions.
ANI Pharmaceuticals reported strong first quarter 2026 growth and raised its full-year outlook. Net revenues reached $237.5 million, up 20.5% year-over-year, led by Rare Disease products and Generics. Cortrophin Gel net revenues were $75.1 million, a 42.1% increase, and ILUVIEN net revenues were $19.3 million, up 19.5%, both mainly driven by higher volume.
GAAP net income available to common shareholders rose to $29.5 million, with diluted GAAP EPS of $1.28, while adjusted non-GAAP diluted EPS was $2.05. Adjusted non-GAAP EBITDA grew 24.1% to $63.0 million. The company now guides 2026 total net revenue to $1.08–$1.14 billion and adjusted non-GAAP EBITDA to $285–$300 million, and expects adjusted non-GAAP diluted EPS of $9.19–$9.69.
ANI reaffirmed 2026 Cortrophin Gel net revenue guidance of $540–$575 million and ILUVIEN guidance of $78–$83 million. The board also authorized a $100 million share repurchase program through May 2029, to be funded with the company’s cash resources.
ANI Pharmaceuticals senior vice president Meredith Cook sold a small block of company stock in a pre-planned trade. Cook executed an open-market sale of 500 shares of ANI Pharmaceuticals common stock at $77.95 per share. After this transaction, she continues to hold 78,890 shares directly, indicating she retains the vast majority of her stake. The sale was carried out under a Rule 10b5-1 trading plan adopted in advance, which means the trade was pre-scheduled rather than timed discretionarily.
ANI Pharmaceuticals, Inc. is asking stockholders to vote at its virtual 2026 annual meeting on May 21, 2026. Holders of 22,750,198 shares of Common Stock and 10,864 shares of Class C Special Stock as of March 23, 2026 can vote one vote per share.
Stockholders will elect seven directors, ratify Ernst & Young LLP as auditor for 2026, cast advisory votes on executive compensation and its future frequency, and approve an Amended and Restated 2022 Stock Incentive Plan. The proxy highlights record 2025 net revenues of $883.4 million, up 43.8%, and adjusted non‑GAAP EBITDA of $229.8 million, up 47.3%, driven by strong Rare Disease and Generics performance.
ANI Pharmaceuticals changed its independent auditor. On April 1, 2026, the company dismissed EisnerAmper LLP as its independent registered public accounting firm and, on the same date, the Audit and Finance Committee approved the appointment of Ernst & Young LLP for the fiscal year ending December 31, 2026.
The company states that EisnerAmper’s audit reports for the years ended December 31, 2025 and 2024 contained no adverse opinions, disclaimers, or qualifications. It also reports no disagreements or reportable events with EisnerAmper during those periods, and has filed EisnerAmper’s response letter as an exhibit.
ANI Pharmaceuticals Inc ownership disclosure: The Vanguard Group amended its Schedule 13G to report it beneficially owns 0 shares of ANI Pharmaceuticals Inc common stock, representing 0%. The filing states an internal realignment on January 12, 2026 led certain Vanguard subsidiaries to report separately under SEC Release No. 34-39538.
ANI Pharmaceuticals senior executive sells part of stake
ANI Pharmaceuticals’ SVP, Head – Established Brands, Thomas Andrew Rowland, reported an open-market sale of 4,772 shares of common stock at an average price of $74.91 per share. After this transaction, he directly holds 38,730 shares, indicating a partial sale while retaining a significant remaining position.
ANI Pharmaceuticals executive Christopher Mutz, Head of Rare Disease, reported an open-market sale of 3,162 shares of Common Stock. The shares were sold on March 13, 2026 at a weighted average price of $71.64 per share, in multiple trades ranging from $70.27 to $72.62.
The transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on June 16, 2025. Following this sale, Mutz directly holds 91,309 shares of ANI Pharmaceuticals common stock.
ANI Pharmaceuticals senior vice president and general counsel Meredith Cook reported a small open-market sale of 500 shares of common stock at $72.62 per share. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 15, 2025.
After this sale, Cook still directly owns 79,390 shares, so the trade represents a minor portion of her overall reported holdings and appears to be a routine, pre-planned liquidity event rather than a major change in ownership.
ANI Pharmaceuticals executive Christopher Mutz reported recent stock transactions in ANI PHARMACEUTICALS INC common shares. He sold 2,121 shares on March 6, 2026 at $74.22 per share and 3,602 shares on March 9, 2026 at $74.18 per share, both as open‑market sales under a Rule 10b5‑1 trading plan adopted on June 16, 2025. Separately, 3,314 shares were withheld on March 7, 2026 at $74.04 per share to cover tax obligations tied to the vesting of 6,476 restricted shares. After these transactions, he directly holds 94,471 shares of ANI common stock.